KMD Bioscience has been deeply engaged in the field of antibody engineering for many years, accumulating extensive technical expertise and a proven track record in antibody humanization. We offer customized, end‑to‑end humanization services to global clients. Our platform covers antibody molecules derived from multiple species, including non‑human primates, mouse, rabbit, alpaca (VHH), chicken, and canine. Depending on the target characteristics, downstream applications, and development stage, we flexibly tailor our technical strategies to meet diverse needs—from basic research to preclinical development.
Therapeutic antibodies have become a cornerstone of modern biopharmaceutical R&D; however, animal‑derived antibodies often elicit anti‑drug antibody (ADA) responses in humans, leading to reduced efficacy and potential safety concerns. Antibody humanization, via genetic engineering, systematically grafts the complementarity‑determining regions (CDRs) of heterologous antibodies onto human framework regions. Combined with structural modeling, computer‑aided design, and affinity maturation technologies, this approach maximally preserves the original binding activity while lowering immunogenicity and improving in vivo half‑life and biocompatibility. At KMD Bioscience, our humanization platform integrates advanced computational modeling, molecular dynamics simulations, and high‑throughput screening to precisely identify key framework residues and optimize back‑mutation sites, ensuring that the resulting humanized antibodies meet stringent clinical standards for affinity, stability, and expression yield.
For VHH antibodies (single‑domain antibodies derived from alpaca), we provide dedicated humanization strategies. Given their simple structure and small molecular size, VHH humanization requires special attention to replacing hydrophobic framework residues and preserving CDR conformations. Through multi‑species germline comparison and stability prediction, we achieve low‑immunogenicity engineering while maintaining the unique antigen‑binding loop architecture. For scFv antibodies, we comprehensively consider linker design, heavy/light chain pairing, and aggregation propensity; our humanization modifications improve solubility and thermostability, thereby laying a solid foundation for subsequent fusion protein or bispecific antibody construction.
Leveraging a skilled technical team and well‑established process workflows, KMD Bioscience offers one‑stop services that span sequence analysis, humanization design, recombinant expression, and functional validation. Driven by continuous innovation, we constantly refine our humanization algorithms and expression systems. We are committed to providing comprehensive technical support to biopharmaceutical clients worldwide, fostering innovation and advancement in antibody drug development.
General Process
Antibody Humanization PlatformGeneral Process
-
Customer Inquiry
-
Plan Confirmation
-
Contract Signing
-
Project Launch
-
Product Delivery
0
